WST:NYE-West Pharmaceutical Services Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 360.43

Change

-7.75 (-2.10)%

Market Cap

USD 5.90B

Volume

0.60M

Analyst Target

USD 265.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

West Pharmaceutical Services Inc develops, manufactures and sells packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, and prefillable syringe components.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+0.57 (+0.24%)

USD 68.37B
ALC Alcon AG

+0.56 (+0.70%)

USD 39.66B
HYB New America High Income Closed..

+0.04 (+0.56%)

USD 35.93B
RMD ResMed Inc

-0.78 (-0.36%)

USD 27.76B
BAX Baxter International Inc

-0.39 (-1.07%)

USD 18.60B
TFX Teleflex Incorporated

+0.56 (+0.28%)

USD 10.10B
ATR AptarGroup Inc

+0.68 (+0.46%)

USD 9.88B
STVN Stevanato Group SpA

+0.97 (+3.64%)

USD 7.29B
BLCO Bausch + Lomb Corp

+0.46 (+3.19%)

USD 5.08B
HAE Haemonetics Corporation

-0.18 (-0.19%)

USD 4.30B

ETFs Containing WST

SANE 6.08 % 0.00 %

N/A

N/A
CB5:LSE Amundi ETF MSCI Europe Ba.. 4.87 % 0.00 %

+301.00 (+0.80%)

USD 0.05B
HLTH:AU VanEck Global Healthcare .. 2.21 % 0.00 %

+0.06 (+0.80%)

USD 0.06B
RSPH Invesco S&P 500® Equal.. 1.71 % 0.00 %

+0.24 (+0.80%)

USD 1.02B
PEXL Pacer US Export Leaders E.. 1.11 % 0.60 %

+0.21 (+0.80%)

USD 0.06B
EQWM 0.00 % 0.25 %

N/A

N/A
MIDZ 0.00 % 0.97 %

N/A

N/A
MYY ProShares Short MidCap400 0.00 % 0.95 %

-0.05 (0.80%)

USD 6.08M
MZZ ProShares UltraShort MidC.. 0.00 % 0.95 %

-0.07 (0.80%)

USD 1.68M
NOBL 0.00 % 0.35 %

N/A

N/A
PXMG 0.00 % 0.39 %

N/A

N/A
PQLC 0.00 % 0.00 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.01 (+0.80%)

CAD 0.05B
SMDD ProShares UltraPro Short .. 0.00 % 0.95 %

-0.11 (0.80%)

USD 3.75M
BMED BlackRock Future Health E.. 0.00 % 0.00 %

+0.13 (+0.80%)

USD 4.21M

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.36% 72% C 57% F
Dividend Return 0.11% 13% F 4% F
Total Return 2.47% 67% D+ 52% F
Trailing 12 Months  
Capital Gain -0.22% 61% D- 39% F
Dividend Return 0.22% 11% F 2% F
Total Return -0.01% 56% F 28% F
Trailing 5 Years  
Capital Gain 191.42% 91% A- 94% A
Dividend Return 2.87% 29% F 9% A-
Total Return 194.29% 91% A- 93% A
Average Annual (5 Year Horizon)  
Capital Gain 34.71% 89% A- 92% A
Dividend Return 35.00% 89% A- 91% A-
Total Return 0.29% 22% F 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 44.15% 39% F 23% F
Risk Adjusted Return 79.28% 100% F 94% A
Market Capitalization 5.90B 78% C+ 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.40 33% 13%
Price/Book Ratio 9.66 11% 8%
Price / Cash Flow Ratio 35.07 18% 7%
Price/Free Cash Flow Ratio 32.30 6% 6%
Management Effectiveness  
Return on Equity 21.32% 94% 84%
Return on Invested Capital 18.51% 94% 85%
Return on Assets 11.93% 100% 95%
Debt to Equity Ratio 2.53% 92% 91%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.